We are live on ! Find out more
NLVP

New Leaf Venture Partners Portfolio holdings

AUM $43M
1-Year Est. Return 25.55%
This Fund
S&P 500
This Quarter Est. Return
+26.24%
1 Year Est. Return
-25.55%
3 Year Est. Return
+17.13%
5 Year Est. Return
+114.46%
10 Year Est. Return
+1,011.57%
AUM
$139M
AUM Growth
+$22.7M
Cap. Flow
-$2.28M
Cap. Flow %
-1.64%
Top 10 Hldgs %
97.44%
Holding
15
New
1
Increased
1
Reduced
4
Closed
1
Avg Time Held
3.4 quarters
Top 10 Avg Time Held
4.3 quarters
Top 20 Avg Time Held
3.4 quarters

Top Buys

Rank Stock Value
1
ALDR
Alder Biopharmaceuticals
ALDR
+$1.22M
2
RCKT icon
Rocket Pharmaceuticals
RCKT
+$395K

Top Sells

Rank Stock Value
1
KPTI icon
Karyopharm Therapeutics
KPTI
+$1.5M
2
SAGE icon
Sage Therapeutics
SAGE
+$988K
3
DVAX icon
Dynavax Technologies
DVAX
+$783K
4
ADAP
Adaptimmune Therapeutics
ADAP
+$549K
5
DERM icon
Dermira, Inc.
DERM
+$83.7K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
WVE icon
1
Wave Life Sciences
WVE
$682M
$25.5M 18.33%
784,159
– –
2015 Q4
3 quarters
ARAV
2
DELISTED
Aravive, Inc. Common Stock
ARAV
$25M 17.98%
339,871
– –
2014 Q4
7 quarters
PDSB icon
3
PDS Biotechnology
PDSB
$100M
$24.4M 17.57%
117,243
– –
2015 Q4
3 quarters
OXFD
4
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$17.3M 12.46%
1,377,497
– –
2014 Q4
7 quarters
DMTX
5
DELISTED
Dimension Therapeutics, Inc
DMTX
$16.5M 11.85%
2,059,283
– –
2015 Q4
3 quarters
ALDR
6
DELISTED
Alder Biopharmaceuticals
ALDR
$7.57M 5.45%
230,954
+40,148
+21% +$1.22M
2014 Q4
7 quarters
DERM icon
7
DELISTED
Dermira, Inc.
DERM
$6.56M 4.72%
193,944
-2,600
-1% -$83.7K
2015 Q2
5 quarters
SAGE icon
8
DELISTED
Sage Therapeutics
SAGE
$6.11M 4.4%
132,674
-24,284
-15% -$988K
2016 Q1
2 quarters
DVAX icon
9
DELISTED
Dynavax Technologies
DVAX
$4.2M 3.02%
400,381
-54,500
-12% -$783K
2014 Q4
7 quarters
AVEO
10
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$2.31M 1.66%
259,067
– –
2016 Q2
1 quarter
VTGN icon
11
VistaGen Therapeutics
VTGN
$10.5M
$1.49M 1.07%
11,765
– –
2016 Q2
1 quarter
TRIL
12
DELISTED
Trillium Therapeutics Inc.
TRIL
$1.19M 0.86%
80,759
– –
2016 Q2
1 quarter
RCKT icon
13
Rocket Pharmaceuticals
RCKT
$281M
$477K 0.34%
+12,575
New +$395K
2016 Q3
0 quarters
ADAP
14
DELISTED
Adaptimmune Therapeutics
ADAP
$388K 0.28%
55,008
-72,033
-57% -$549K
2016 Q2
1 quarter
KPTI icon
15
Karyopharm Therapeutics
KPTI
$13.7M
– –
-14,863
Closed -$1.5M –

Similar funds

BAM
Broadcrest Asset Management Winter Park, Florida $44.1M AUM 4.51% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
WCPI
Wynnchurch Capital Partners IV Rosemont, Illinois $44.8M AUM 11.91% 1-Year Est. Return
WAMC
Western Asset Management Company Pasadena, California $45.2M AUM 6.96% 1-Year Est. Return
CC
Corton Capital Carrying Place, Ontario, Canada $40.7M AUM 52.32% 1-Year Est. Return
CIEP
Constellation Investimentos e Participacoes Sao Paulo, Brazil $46.7M AUM 23.3% 1-Year Est. Return
IPI
Inflection Point Investments London, United Kingdom $46.9M AUM 18.35% 1-Year Est. Return
VSAM
Value Star Asset Management Hong Kong $49.2M AUM 60.1% 1-Year Est. Return

New Leaf Venture Partners's Q3 2016 Portfolio in Review

As of Q3 2016, New Leaf Venture Partners held 15 positions worth $139M, up 20% from $116M the previous quarter. Its ten largest holdings account for 97% of the portfolio.

New Leaf Venture Partners's Q3 2016 filing shows 1 new, 1 increased, 4 reduced and 1 closed positions. Its largest new stake was Rocket Pharmaceuticals: 12,575 shares worth $477K. The largest sale was Karyopharm Therapeutics, an estimated $1.5M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • New Leaf Venture Partners's largest Q3 2016 buy was Rocket Pharmaceuticals: 12,575 shares worth $477K.
  • New Leaf Venture Partners added most to Alder Biopharmaceuticals in Q3 2016, an estimated $1.22M increase.
  • New Leaf Venture Partners's biggest Q3 2016 reduction was Sage Therapeutics, cutting an estimated $988K.
  • New Leaf Venture Partners fully exited Karyopharm Therapeutics in Q3 2016, selling an estimated $1.5M.
  • New Leaf Venture Partners's ten largest holdings make up 97% of its $139M portfolio in Q3 2016.
  • New Leaf Venture Partners opened 1 new position and closed 1 in Q3 2016.
  • New Leaf Venture Partners's portfolio value rose 20% quarter-over-quarter to $139M.

Based on New Leaf Venture Partners's 13F filing for Q3 2016, filed 14 Nov 2016.